SCHEMBL6833460

SCHEMBL6833460

COc1ccc(S(=O)(=O)Nc2cccc(/C(=C\C(=O)O)c3ccccc3)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TCF4 P15884 2/20 0.69
CTNNB1 P35222 2/20 0.69
HTT P42858 3/20 0.62
THRB P10828 1/20 0.62
CYP19A1 P11511 1/20 0.62
ALDH1A1 P00352 3/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
KDM4E B2RXH2 2/20 0.57
LMNA P02545 2/20 0.57
MAPT P10636 2/20 0.57
HPGD P15428 2/20 0.57
GAA P10253 1/20 0.57
LIMK2 P53671 1/20 0.53
EGFR P00533 1/20 0.53
FGFR1 P11362 1/20 0.53
KDR P35968 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ALOX12 P18054 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6833462 1.00 TCF4 (0.69) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL6834499 0.98 TCF4 (0.72) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL6834488 0.90 TCF4 (0.65) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL6834490 0.90 TCF4 (0.65) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL6834529 0.90 TCF4 (0.65) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL6834222 0.90 LIMK2 (0.62) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL6834224 0.90 LIMK2 (0.62) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL7163569 0.89 TCF4 (0.60) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL6830952 0.87 TCF4 (0.61) TCF4CTNNB1HTTTHRBCYP19A1
SCHEMBL6830949 0.87 TCF4 (0.61) TCF4CTNNB1HTTTHRBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040029928-A1 Novel propenohydroxamic acid derivatives WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2004-02-12 US disclosed
EP-1314721-A1 NOVEL PROPENOHYDROXAMIC ACID DERIVATIVES WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040029928-A1 Novel propenohydroxamic acid derivatives TNF, SI, HDGF TCF4 2045/4885CTNNB1 1993/4885HTT 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.